WO2024189048 - SUBCUTANEOUSLY ADMINISTERED ANTIBODY-DRUG CONJUGATES FOR USE IN CANCER TREATMENT
National phase entry:
Publication Number
WO/2024/189048
Publication Date
19.09.2024
International Application No.
PCT/EP2024/056594
International Filing Date
12.03.2024
Title **
[English]
SUBCUTANEOUSLY ADMINISTERED ANTIBODY-DRUG CONJUGATES FOR USE IN CANCER TREATMENT
[French]
CONJUGUÉS ANTICORPS-MÉDICAMENT ADMINISTRÉS PAR VOIE SOUS-CUTANÉE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DU CANCER
Applicants **
HEIDELBERG PHARMA RESEARCH GMBH
Gregor-Mendel-Str. 22
68526 Ladenburg, DE
Inventors
KULKE, Michael
c/o Heidelberg Pharma Research GmbH,
Gregor-Mendel-Str. 22
68526 Ladenburg, DE
HECHLER, Torsten
c/o Heidelberg Pharma Research GmbH,
Gregor-Mendel-Str. 22
68526 Ladenburg, DE
DECKER, Kristin
c/o Heidelberg Pharma Research GmbH,
Gregor-Mendel-Str. 22
68526 Ladenburg, DE
PAHL, Andreas
c/o Heidelberg Pharma Research GmbH,
Gregor-Mendel-Str. 22
68526 Ladenburg, DE
STRASSZ, András
c/o Heidelberg Pharma Research GmbH,
Gregor-Mendel-Str. 22
68526 Ladenburg, DE
Priority Data
23161638.4
13.03.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter II
* |
| * | |
| * | |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2338 | |
| EPO | Filing, Examination | 13764 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 6560 |
Total: 23,826 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present application pertains to pharmaceutical compositions for use in the treatment of cancer, whereby said pharmaceutical compositions are administered subcutaneously and wherein the pharmaceutical compositions of the invention comprise at least one conjugate that comprises an antibody which specifically binds to a cell surface antigen on a cancer cell and at least one amatoxin-linker payload. The present invention further pertains to methods of treating a patient afflicted with cancer using the pharmaceutical compositions of the invention.[French]
La présente demande concerne des compositions pharmaceutiques destinées à être utilisées dans le traitement du cancer, lesdites compositions pharmaceutiques étant administrées par voie sous-cutanée et les compositions pharmaceutiques de l'invention comprenant au moins un conjugué qui comprend un anticorps qui se lie spécifiquement à un antigène de surface cellulaire sur une cellule cancéreuse et au moins une charge utile de lieur d'amatoxine. La présente invention concerne en outre des méthodes de traitement d'un patient atteint d'un cancer à l'aide des compositions pharmaceutiques de l'invention.